# CheckMate 274 (NCT02632409)

> An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02632409
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Various Advanced Cancer
- Interventions: Nivolumab; Placebo
- Enrollment: 709
- Primary outcome: Disease Free Survival (DFS)
- Primary outcome: Disease Free Survival (DFS) in PD-L1 Expression ≥ 1% Population

## Commentary we found

- YouTube: 116
- X threads: 95
- Podcasts: 84
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-274-nct02632409

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02632409", "email": "<work email>"}; the inbox owner confirms by the emailed link.